TOP > 外国特許検索 > BLOOD BIOMARKER FOR USE IN EVALUATION OF EFFECT OF DRUG THERAPY ON KIDNEY CANCER

BLOOD BIOMARKER FOR USE IN EVALUATION OF EFFECT OF DRUG THERAPY ON KIDNEY CANCER

外国特許コード F170009087
整理番号 (S2016-0050-N0)
掲載日 2017年5月30日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP080084
国際公開番号 WO 2017065127
国際出願日 平成28年10月11日(2016.10.11)
国際公開日 平成29年4月20日(2017.4.20)
優先権データ
  • 特願2015-202614 (2015.10.14) JP
発明の名称 (英語) BLOOD BIOMARKER FOR USE IN EVALUATION OF EFFECT OF DRUG THERAPY ON KIDNEY CANCER
発明の概要(英語) Disclosed is a means whereby it becomes possible to evaluate the efficacy of a drug therapy agent on kidney cancer by a blood test in a simple manner. A method for assisting the evaluation of the effect of a drug therapy for the treatment of kidney cancer according to the present invention involves measuring the PARK7 level in a blood sample isolated from a kidney cancer patient who has been received the drug therapy for treating kidney cancer. An increased PARK7 level serves as a measure of a fact that the drug therapy is less effective. The efficacy of a candidate substance for a therapeutic drug for kidney cancer can be evaluated by employing a blood PARK7 level as a measure.
特許請求の範囲(英語) [claim1]
1. The fact that PARK7 level in the blood sample which is separated from the kidney cancer patient who receives the medicine medical therapy for kidney cancer remedy is measured is included, being the method effective decision of the aforementioned medicine medical therapy being assisted, rise of PARK7 level becomes index of the thing whose particular medicine medical therapy is not effective, method.
[claim2]
2. Whether or not PARK7 level rose, but is judged the aforementioned patient by the comparison with the previous measurable quantity at least, method of claim 1 statement.
[claim3]
3. The aforementioned blood sample is the blood plasma sample or the serum sample, claim method of 1 or 2 statements.
[claim4]
4. The use of PARK7 as a bio marker in the effective decision blood of kidney cancer medicine medical therapy.
[claim5]
5. It consists of PARK7, the bio marker in the effective decision blood of kidney cancer medicine medical therapy.
[claim6]
6. Being the method of assisting the effective decision of the candidacy substance of the kidney cancer remedy, it includes the fact that it measures the PARK7 level in the blood sample which is separated before the prescribing the aforementioned candidacy substance and after the prescribing from the suffering inspection body which possesses the kidney cancer, it is decided, that when the PARK7 level in the blood sample after the prescribing by comparison with the PARK7 level in the blood sample before the prescribing has decreased, there is a possibility the particular candidacy substance being effective to kidney cancer remedy method.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • YOKOHAMA CITY UNIVERSITY
  • 発明者(英語)
  • NAKAIGAWA NOBORU
  • UENO DAIKI
  • YAO MASAHIRO
国際特許分類(IPC)
指定国 (WO201765127)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
※ ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close